X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.biopharmadive.com/news/bristol-myers-layoffs-restructuring-cost-savings/714254/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210091
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210066
https://www.fiercepharma.com/pharma/cost-watchdog-icer-chips-medicares-looming-price-negotiations-appraisal-eliquis-and-xarelto
https://www.reuters.com/business/healthcare-pharmaceuticals/us-name-first-10-drugs-medicare-price-negotiation-2023-08-29/
https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-pfizer-abbvie-drugs-likely-face-us-price-negotiation-2023-03-13/
https://health.economictimes.indiatimes.com/news/pharma/zydus-lifesciences-gets-usfda-nod-to-market-generic-drug/98320181
https://www.clinicaltrialsarena.com/news/anticoagulant-covid-trial/
https://tiefenbachergroup.com/2022/10/20/new-market-launch-tiefenbacher-pharmaceuticals-successfully-launches-generic-version-of-the-anticoagulant-medicine-apixaban-in-canada/
https://endpts.com/cvs-resumes-coverage-of-blockbuster-blood-thinner-after-price-drop-follows-january-exclusion/
https://www.fiercepharma.com/pharma/eliquis-will-return-cvs-formulary-after-wave-criticism-cites-lower-net-cost-negotiations-bms
https://www.pharmatimes.com/news/teva_uk_introduces_first_generic_oral_anticoagulant_1449480
https://endpts.com/bristol-myers-squibb-refreshes-eliquis-campaign-adds-eye-catching-animations-in-tv-ads/
https://www.forbes.com/sites/greatspeculations/2022/04/28/what-to-expect-from-bristol-myers-squibb-stock-after-q1-results/?sh=1516cc674893
https://www.fiercepharma.com/marketing/bms-pfizer-alliance-double-down-heart-health-renewed-no-time-to-wait-campaign
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210053
https://www.fiercepharma.com/marketing/december-sees-new-players-move-into-top-10-tv-ad-spend-list-as-sanofi-regeneron-s
https://endpts.com/cvs-takes-a-swing-at-bristol-myers-and-pfizer-excluding-coverage-of-their-megablockbuster-eliquis-in-2022/
https://www.fiercepharma.com/pharma/revlimid-erosion-coming-bristol-myers-squibb-encouraged-by-performance-new-car-ts-abecma
https://www.globenewswire.com/news-release/2021/10/04/2307727/0/en/New-data-in-the-European-Heart-Journal-show-ciraparantag-reverses-the-anticoagulant-activity-of-apixaban-and-rivaroxaban-in-elderly-patients.html
https://www.globenewswire.com/news-release/2021/10/04/2307727/0/en/New-data-in-the-European-Heart-Journal-show-ciraparantag-reverses-the-anticoagulant-activity-of-apixaban-and-rivaroxaban-in-elderly-patients.html
https://www.biospace.com/article/apixaban-drug-market-rise-in-prevalence-of-venous-thromboembolism-related-diseases-is-projected-to-boost-the-market/
https://www.prnewswire.com/news-releases/instrumentation-laboratory-receives-us-fda-marketing-authorization-for-the-first-apixaban-diagnostic-test-301135330.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209898
https://www.expresspharma.in/drug-approvals/indoco-gets-usfda-nod-for-apixaban-tablets/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210053
https://endpts.com/covid-19-roundup-all-it-took-was-a-pandemic-to-get-jpm-out-of-sf-would-you-take-a-vaccine-before-election-day/
http://www.pharmatimes.com/news/nice_backs_portolas_ondexxya_1349854
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210053
https://www.FIERCE PHARMA.com/pharma/esc-pfizer-bms-eliquis-cuts-site-specific-bleeding-over-vkas-xarelto-french-real-world-study
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210180
https://www.marketwatch.com/press-release/amag-announces-presentation-of-ciraparantag-data-at-the-international-society-on-thrombosis-and-haemostasis-2020-07-12?tesla=y
http://www.pharmatimes.com/news/new_vaccine_for_ebola_among_chmp_recommendations_1341219
https://www.fiercepharma.com/pharma/covid-drives-huge-demand-for-bristol-myers-blood-thinner-eliquis-but-could-dampen-mid-year
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210152
https://www.ema.europa.eu/en/news/no-change-needed-use-direct-oral-anticoagulants-following-ema-funded-study
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/hc-bars-cipla-3-others-from-launching-generic-version-of-bristol-myers-drug/articleshow/73183597.cms
https://www.fiercepharma.com/pharma/pfizer-bms-gilead-abbvie-and-others-raise-prices-hundreds-medicines-to-ring-2020
https://www.reuters.com/article/us-mylan-nl-fda-bristol-myers/fda-approves-first-generic-of-bristol-myers-pfizers-blood-thinner-eliquis-idUSKBN1YR20W
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210128
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210013
https://www.fiercepharma.com/pharma/pfizer-bms-look-to-early-atrial-fibrillation-screening-for-possible-eliquis-boost
https://www.fiercepharma.com/pharma/pharma-shares-slide-after-democrats-aggressive-drug-pricing-plan-leaks
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209944
https://www.fiercepharma.com/pharma/esc-pfizer-bms-eliquis-adds-to-lead-competitor-topping-french-real-world-data
https://news.bms.com/press-release/rd-news/findings-released-naxos-french-real-world-data-analysis-and-largest-real-world
https://www.reuters.com/article/bristol-myers-results/bristol-myers-posts-strong-second-quarter-earnings-as-eliquis-orencia-surprise-idUSL2N24P210
https://www.fiercepharma.com/pharma/j-j-strives-for-above-market-growth-despite-challenges-for-zytiga-xarelto
https://www.fiercepharma.com/marketing/gildead-biktarvy-jumps-to-no-2-pharma-tv-ad-spending-for-june-pfizer-xeljanz-drops-off
Market Place
Share 
